Hunan Er-Kang Pharmaceutical Co., Ltd

SZSE:300267 Stock Report

Market Cap: CN¥5.9b

Hunan Er-Kang Pharmaceutical Dividends and Buybacks

Dividend criteria checks 0/6

Hunan Er-Kang Pharmaceutical does not currently pay a dividend.

Key information

0%

Dividend yield

-0.5%

Buyback Yield

Total Shareholder Yield-0.5%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per shareCN¥0.030
Payout ratio0%

Recent dividend and buyback updates

Recent updates

Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%

Sep 30
Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%

Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?

Sep 26
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?

What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You

Aug 08
What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You

Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?

Jun 03
Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?

Pinning Down Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) P/S Is Difficult Right Now

Mar 27
Pinning Down Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) P/S Is Difficult Right Now

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if 300267's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 300267's dividend payments have been increasing.


Dividend Yield vs Market

Hunan Er-Kang Pharmaceutical Dividend Yield vs Market
How does 300267 dividend yield compare to the market?
SegmentDividend Yield
Company (300267)0%
Market Bottom 25% (CN)0.5%
Market Top 25% (CN)2.1%
Industry Average (Pharmaceuticals)1.8%
Analyst forecast (300267) (up to 3 years)n/a

Notable Dividend: Unable to evaluate 300267's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 300267's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: 300267 is not paying a notable dividend for the CN market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 300267 has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 21:25
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hunan Er-Kang Pharmaceutical Co., Ltd is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yalei YanBohai Securities Co., Ltd.
Shuchang LiuChangjiang Securities Co. LTD.
Jing QiangChina International Capital Corporation Limited